208 related articles for article (PubMed ID: 34782365)
1. T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas.
Kilian M; Friedrich M; Sanghvi K; Green E; Pusch S; Kawauchi D; Löwer M; Sonner JK; Krämer C; Zaman J; Jung S; Breckwoldt MO; Willimsky G; Eichmüller SB; von Deimling A; Wick W; Sahm F; Platten M; Bunse L
Clin Cancer Res; 2022 Jan; 28(2):378-389. PubMed ID: 34782365
[TBL] [Abstract][Full Text] [Related]
2. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
3. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.
Chheda ZS; Kohanbash G; Okada K; Jahan N; Sidney J; Pecoraro M; Yang X; Carrera DA; Downey KM; Shrivastav S; Liu S; Lin Y; Lagisetti C; Chuntova P; Watchmaker PB; Mueller S; Pollack IF; Rajalingam R; Carcaboso AM; Mann M; Sette A; Garcia KC; Hou Y; Okada H
J Exp Med; 2018 Jan; 215(1):141-157. PubMed ID: 29203539
[TBL] [Abstract][Full Text] [Related]
4. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
5. NLGN4X TCR transgenic T cells to treat gliomas.
Krämer C; Kilian M; Chih YC; Kourtesakis A; Hoffmann DC; Boschert T; Koopmann P; Sanghvi K; De Roia A; Jung S; Jähne K; Day B; Shultz LD; Ratliff M; Harbottle R; Green EW; Will R; Wick W; Platten M; Bunse L
Neuro Oncol; 2024 Feb; 26(2):266-278. PubMed ID: 37715782
[TBL] [Abstract][Full Text] [Related]
6. Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors.
Immisch L; Papafotiou G; Gallarín Delgado N; Scheuplein V; Paschen A; Blankenstein T; Willimsky G
Front Immunol; 2023; 14():1119498. PubMed ID: 36875127
[TBL] [Abstract][Full Text] [Related]
7.
Hunger J; Schregel K; Boztepe B; Agardy DA; Turco V; Karimian-Jazi K; Weidenfeld I; Streibel Y; Fischer M; Sturm V; Santarella-Mellwig R; Kilian M; Jähne K; Sahm K; Wick W; Bunse L; Heiland S; Bunse T; Bendszus M; Platten M; Breckwoldt MO
Theranostics; 2023; 13(15):5170-5182. PubMed ID: 37908732
[No Abstract] [Full Text] [Related]
8. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
9. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
10. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
11. Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging.
Liu K; Liu X; Peng Z; Sun H; Zhang M; Zhang J; Liu S; Hao L; Lu G; Zheng K; Gong X; Wu D; Wang F; Shen L
Oncotarget; 2015 Sep; 6(27):23735-47. PubMed ID: 26124178
[TBL] [Abstract][Full Text] [Related]
12. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
13. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
14. Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy of non-microsatellite instability-high colorectal cancer.
Shi R; Li Y; Ran L; Dong Y; Zhou X; Tang J; Han L; Wang M; Pang L; Qi Y; Wu Y; Gao Y
Sci China Life Sci; 2022 Mar; 65(3):572-587. PubMed ID: 34236583
[TBL] [Abstract][Full Text] [Related]
15. K27M-mutant histone-3 as a novel target for glioma immunotherapy.
Ochs K; Ott M; Bunse T; Sahm F; Bunse L; Deumelandt K; Sonner JK; Keil M; von Deimling A; Wick W; Platten M
Oncoimmunology; 2017; 6(7):e1328340. PubMed ID: 28811969
[TBL] [Abstract][Full Text] [Related]
16. A vaccine targeting mutant IDH1 induces antitumour immunity.
Schumacher T; Bunse L; Pusch S; Sahm F; Wiestler B; Quandt J; Menn O; Osswald M; Oezen I; Ott M; Keil M; Balß J; Rauschenbach K; Grabowska AK; Vogler I; Diekmann J; Trautwein N; Eichmüller SB; Okun J; Stevanović S; Riemer AB; Sahin U; Friese MA; Beckhove P; von Deimling A; Wick W; Platten M
Nature; 2014 Aug; 512(7514):324-7. PubMed ID: 25043048
[TBL] [Abstract][Full Text] [Related]
17. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.
Yao X; Lu YC; Parker LL; Li YF; El-Gamil M; Black MA; Xu H; Feldman SA; van der Bruggen P; Rosenberg SA; Robbins PF
J Immunother; 2016 Jun; 39(5):191-201. PubMed ID: 27163739
[TBL] [Abstract][Full Text] [Related]
18. CD70, a novel target of CAR T-cell therapy for gliomas.
Jin L; Ge H; Long Y; Yang C; Chang YE; Mu L; Sayour EJ; De Leon G; Wang QJ; Yang JC; Kubilis PS; Bao H; Xia S; Lu D; Kong Y; Hu L; Shang Y; Jiang C; Nie J; Li S; Gu Y; Sun J; Mitchell DA; Lin Z; Huang J
Neuro Oncol; 2018 Jan; 20(1):55-65. PubMed ID: 28651374
[TBL] [Abstract][Full Text] [Related]
19. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.
Koya RC; Mok S; Comin-Anduix B; Chodon T; Radu CG; Nishimura MI; Witte ON; Ribas A
Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14286-91. PubMed ID: 20624956
[TBL] [Abstract][Full Text] [Related]
20. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
